AtriCure Narrows Losses on Strong 15.8% Revenue Growth

TL;DR

**ATRC is showing strong top-line growth and narrowing losses, making it a compelling buy for long-term growth in medical devices.**

AI Summary

AtriCure, Inc. reported a significant increase in revenue for the three months ended September 30, 2025, reaching $134.269 million, up from $115.910 million in the prior year, representing a 15.8% increase. For the nine months ended September 30, 2025, revenue grew to $394.028 million from $341.030 million, a 15.5% increase. The company achieved income from operations of $0.208 million for the three-month period, a substantial improvement from a loss of $7.405 million in the same period last year. Despite this operational improvement, AtriCure still posted a net loss of $0.267 million for the quarter, though significantly reduced from a net loss of $7.853 million in Q3 2024. The nine-month net loss also improved to $13.204 million from $29.130 million. Cash and cash equivalents increased to $147.865 million as of September 30, 2025, from $122.721 million at December 31, 2024, driven by $37.307 million in net cash provided by operating activities for the nine-month period. The company's total assets grew to $635.442 million from $609.328 million, while total liabilities increased to $158.935 million from $148.359 million.

Why It Matters

AtriCure's ability to significantly narrow its net loss while achieving robust revenue growth signals a positive trajectory for investors, suggesting improved operational efficiency and market penetration in the surgical treatment space for atrial fibrillation. This performance could strengthen investor confidence, potentially leading to increased stock valuation. For employees, continued growth and a path towards profitability could mean greater job security and opportunities. Customers, primarily medical centers, benefit from AtriCure's innovation in cardiac tissue ablation and LAA management, indicating a healthy competitive landscape in medical devices. The broader market sees a medical device company making strides in addressing prevalent cardiac conditions, potentially driving further innovation in the sector.

Risk Assessment

Risk Level: medium — While AtriCure demonstrated strong revenue growth and reduced net losses, it continues to operate at a net loss of $0.267 million for the quarter and $13.204 million for the nine months ended September 30, 2025. The company also has a significant accumulated deficit of $414.959 million, indicating a history of unprofitability. Additionally, the contingent consideration related to the SentreHEART acquisition, specifically the PMA approval milestone, expired December 31, 2023, and the reimbursement milestone expires December 31, 2026, with the probability of payment assessed as remote, which could signal challenges in achieving key commercialization targets.

Analyst Insight

Investors should consider initiating or increasing a position in ATRC, focusing on its strong revenue growth and improving operational efficiency. Monitor future filings for continued progress towards sustained profitability and successful commercialization of its medical devices, particularly regarding the reimbursement milestone for SentreHEART's devices.

Financial Highlights

debt To Equity

0.33

revenue

$394.028M

operating Margin

-3.0%

total Assets

$635.442M

total Debt

$61.865M

net Income

$(13.204)M

eps

$(-0.28)

gross Margin

75.0%

cash Position

$147.865M

revenue Growth

+15.5%

Key Numbers

• $134.269M — Revenue for Q3 2025 (Increased by 15.8% from $115.910 million in Q3 2024)
• $394.028M — Revenue for nine months ended Sept 30, 2025 (Increased by 15.5% from $341.030 million in the prior year period)
• $0.208M — Income from operations for Q3 2025 (Significant improvement from a $7.405 million loss in Q3 2024)
• $(0.267)M — Net loss for Q3 2025 (Reduced from a net loss of $7.853 million in Q3 2024)
• $(13.204)M — Net loss for nine months ended Sept 30, 2025 (Reduced from a net loss of $29.130 million in the prior year period)
• $147.865M — Cash and cash equivalents as of Sept 30, 2025 (Increased from $122.721 million at Dec 31, 2024)
• $37.307M — Net cash provided by operating activities for nine months ended Sept 30, 2025 (Increased from $6.368 million in the prior year period)
• $414.959M — Accumulated deficit as of Sept 30, 2025 (Indicates historical unprofitability)
• 49,716,988 — Common shares outstanding as of Oct 27, 2025 (Reflects total shares outstanding)
• $61.865M — Long-term debt as of Sept 30, 2025 (Due upon maturity of the ABL Facility on January 5, 2027)

Key Players & Entities

• AtriCure, Inc. (company) — Registrant and leading innovator in surgical treatments
• JPMorgan Chase Bank, N.A. (company) — Administrative agent, bookrunner, and lead arranger for the ABL Facility
• Silicon Valley Bank (company) — Joint Lead Arranger and Joint Bookrunner for the ABL Facility
• SentreHEART (company) — Acquired company with contingent consideration arrangements
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• NASDAQ Global Market (regulator) — Exchange where Common Stock is registered
• Chief Executive Officer (person) — Chief operating decision maker

FAQ

Risk Factors

• Dependence on Key Personnel and Product Development [medium — operational]: The company's success is significantly tied to its ability to retain key scientific, engineering, and management personnel and to continue its product development efforts. The loss of key personnel or failure to innovate could materially impact future growth and profitability.
• Regulatory Approval and Compliance [high — regulatory]: AtriCure's medical devices require stringent regulatory approvals (e.g., FDA in the U.S., CE Mark in Europe). Delays in obtaining or maintaining these approvals, or failure to comply with evolving regulatory requirements, could hinder market access and sales.
• Competition and Market Adoption [medium — market]: The company faces competition from established medical device manufacturers and emerging players. The rate of adoption of its minimally invasive surgical solutions by physicians and hospitals is critical to revenue growth.
• Sustained Net Losses and Accumulated Deficit [medium — financial]: Despite revenue growth, AtriCure has historically incurred net losses, resulting in a significant accumulated deficit of $414.959 million as of September 30, 2025. Continued losses could impact the company's ability to fund operations and future growth.
• Long-Term Debt Maturity [medium — financial]: The company has $61.865 million in long-term debt due upon maturity of the ABL Facility on January 5, 2027. The ability to refinance or repay this debt will be a key financial consideration.

Industry Context

AtriCure operates in the highly competitive medical device market, specifically focusing on solutions for atrial fibrillation and left atrial appendage closure. The industry is characterized by rapid technological advancements, stringent regulatory oversight, and a need for strong clinical evidence to drive adoption. Key trends include the shift towards minimally invasive procedures and the increasing demand for innovative therapies to address cardiovascular diseases.

Regulatory Implications

AtriCure's medical devices are subject to rigorous regulatory scrutiny by bodies like the FDA and international equivalents. Compliance with evolving regulations, obtaining and maintaining market approvals, and managing post-market surveillance are critical. Any failure in these areas can lead to significant delays, product recalls, or market withdrawal, impacting revenue and reputation.

What Investors Should Do

1. Monitor revenue growth trajectory and gross margin trends.
2. Assess the path to profitability and cash flow generation.
3. Evaluate the company's debt management strategy.

Key Dates

• 2025-09-30: End of Q3 2025 and Nine-Month Period — Reporting period for the financial results, showing revenue growth and improved operational loss.
• 2025-12-31: End of Fiscal Year 2024 — Prior period balance sheet comparison point for cash and cash equivalents.
• 2027-01-05: ABL Facility Maturity Date — Key date for the maturity of $61.865 million in long-term debt, requiring refinancing or repayment.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates AtriCure's history of net losses, standing at $414.959 million as of September 30, 2025.)

Operating lease right-of-use assets

An asset representing the lessee's right to use an underlying asset for the lease term. (Part of AtriCure's non-current assets, reflecting its obligations for leased properties or equipment.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (A significant intangible asset for AtriCure, valued at $234.781 million, likely from past acquisitions.)

ABL Facility

Asset-Based Lending Facility, a type of revolving credit facility secured by a company's assets. (The source of AtriCure's long-term debt of $61.865 million, with a maturity date in January 2027.)

Year-Over-Year Comparison

AtriCure has shown significant year-over-year improvement in its Q3 2025 results compared to Q3 2024. Revenue increased by 15.8% to $134.269 million, and critically, the company moved from a substantial operating loss of $7.405 million to a small operating income of $0.208 million. This operational improvement also led to a reduced net loss of $0.267 million, down from $7.853 million. The nine-month period also reflects this positive trend with revenue up 15.5% and net loss significantly reduced. Cash reserves have also grown, indicating improved financial health.

Filing Documents

• atrc-20250930.htm (10-Q) — 863KB
• exhibit311-930202510xq.htm (EX-31.1) — 10KB
• exhibit312-930202510xq.htm (EX-31.2) — 10KB
• exhibit321-930202510xq.htm (EX-32.1) — 6KB
• exhibit322-930202510xq.htm (EX-32.2) — 6KB
• atrc-20250930_g1.jpg (GRAPHIC) — 41KB
• 0001323885-25-000103.txt ( ) — 5769KB
• atrc-20250930.xsd (EX-101.SCH) — 36KB
• atrc-20250930_cal.xml (EX-101.CAL) — 75KB
• atrc-20250930_def.xml (EX-101.DEF) — 137KB
• atrc-20250930_lab.xml (EX-101.LAB) — 555KB
• atrc-20250930_pre.xml (EX-101.PRE) — 365KB
• atrc-20250930_htm.xml (XML) — 797KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION 23 Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Other Information

Item 5. Other Information 23 Item 6. Exhibits 24

Signatures

Signatures 25 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Per Share Amounts) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 147,865 $ 122,721 Accounts receivable, less allowance for credit losses of $ 650 and $ 550 62,980 60,339 Inventories 78,951 75,335 Prepaid and other current assets 11,314 9,431 Total current assets 301,110 267,826 Property and equipment, net 39,551 41,659 Operating lease right-of-use assets 6,800 5,727 Intangible assets, net 50,136 56,467 Goodwill 234,781 234,781 Other noncurrent assets 3,064 2,868 Total Assets $ 635,442 $ 609,328 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 25,472 $ 25,032 Accrued liabilities 49,370 45,587 Other current liabilities 2,998 2,805 Total current liabilities 77,840 73,424 Long-term debt 61,865 61,865 Finance and operating lease liabilities 11,867 11,860 Other noncurrent liabilities 7,363 1,210 Total Liabilities 158,935 148,359 Commitments and contingencies (Note 8) Stockholders' Equity: Common stock, $ 0.001 par value, 90,000 shares authorized and 49,713 and 48,869 issued and outstanding 50 49 Additional paid-in capital 890,843 863,710 Accumulated other comprehensive income (loss) 573 ( 1,035 ) Accumulated deficit ( 414,959 ) ( 401,755 ) Total Stockholders' Equity 476,507 460,969 Total Liabilities and Stockholders' Equity $ 635,442 $ 609,328 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue $ 134,269 $ 115,910 $ 394,028 $ 341,030 Cost of revenue 32,937 29,117 98,586 86,125 Gross profit 101,332 86,793 295,442 254,905 Operating

View Full Filing

View this 10-Q filing on SEC EDGAR